NasdaqGS:IRTCMedical Equipment
AMALFI Study’s Positive Results Could Be a Game Changer for iRhythm Technologies (IRTC)
iRhythm Technologies recently announced results from the Oxford University-led AMALFI randomized clinical trial, which found that home-based screening with the Zio long-term continuous monitoring service enabled earlier and more frequent atrial fibrillation detection among high-risk, older adults over 2.5 years of follow-up.
The study’s all-remote design and high device adherence rates suggest strong feasibility for large-scale population screening outside specialist settings, highlighting...